• Antengene dosed the first patient in China in its Phase I ATTRACT trial of ATG-201 for adults with B-cell-mediated autoimmune diseases.
• The China-Australia study will evaluate safety, tolerability and preliminary efficacy to determine a recommended Phase II dose.
• ATG-201 is a CD19-targeting bispecific T-cell engager designed to eliminate B cells implicated in autoimmune disease.
• UCB holds exclusive worldwide development, manufacturing and commercialization rights to ATG-201; Antengene will conduct the Phase I trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611051930PR_NEWS_USPR_____CN89057) on November 06, 2026, and is solely responsible for the information contained therein.